The Top 5 Biosimilars Articles for the Week of August 27
The Center for Biosimilars® recaps the top news for the week of August 27, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 27.
Number 5: The Canadian province of British Columbia will begin reimbursing for a second biosimilar infliximab.
Number 4: Carlos Sattler, head of clinical development and medical affairs at Sandoz, spoke with The Center for Biosimilars® about the biosimilar development process and the regulatory landscape that lies ahead.
Number 3: The World Health Organization says that promoting the uptake of lower-priced medicines such as generics and biosimilars will “facilitate efficiency gains without disadvantaging patients.”
Number 2: Gillian Woollett of Avalere Health says many phase 3 trials of biosimilars lack scientific and ethical validity.
Number 1: Pfizer has submitted a citizen petition to the FDA that asks for guidance that clarifies how drug sponsors may communicate about biosimilars.
Finally, last week, our e-newsletter asked whether you think that a new CVS Caremark policy that will allow health plans to exclude high-cost drugs will result in better negotiation on drug prices.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Recent Findings Highlight Need for Policy Changes for Biosimilars, Follow-on Biologics
